Trial of online support for primary care patients tapering off antidepressant medicatio

Not Applicable

• Conditions: Decreasing antidepressant (AD) medication for depression; Mental and Behavioural Disorders

• Registration Number: ISRCTN11562922
• Lead Sponsor: niversity of Melbourne

Brief Summary

2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38355180/ (added 15/02/2024)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-05-05
• Last Update Posted: 27 February 2024
• Study Completion: 2025-08-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 312

Inclusion Criteria

1. 18-75 years
2. Stable on AD for >=12m: (no depressive episodes)
3. No history of recurrent depression
4. Sufficient English language proficiency to provide informed consent
5. No or mild depressive symptoms as measured on the Personal Health Questionnaire (PHQ9)
6. Low risk of Suicide or Self-harm
7. Agree to consider reviewing their AD use
8. Agree to be randomized into the study
9. Willing to provide informed consent

Exclusion Criteria

1. Those currently experiencing a major life event in the next 3 months
2. Currently using ADs for any other health condition (other than depression)
3. Currently using non-SSRI or SNRI ADs, antipsychotics, or other mood stabiliser medication
4. Have no daily access to the internet

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients successfully ceasing ADs at 6 months where successful cessation is defined as no AD use (as measured by the Resource Use Questionnaire (RUQ)) and the absence of clinically significant depressive symptoms (as measured by the Patient Health Questionnaire 9-item (PHQ-9)). Measured at 3-, 6-, 12-, 18-months post-baseline. Primary outcome is at 6-months post baseline.